Expands Medicare coverage for people at risk of hereditary cancers by requiring coverage of germline (inherited) cancer gene mutation testing according to evidence-based oncology guidelines, treating guideline-recommended risk‑reducing surgeries as medically necessary, and allowing more frequent guideline-driven cancer screening for people with hereditary cancer gene mutations. The law directs use of nationally recognized clinical practice guidelines and lets Medicare administrative contractors pick the least restrictive guideline when multiple guidelines conflict; all changes apply to items and services furnished on or after the date of enactment.